

ASIAN HOTELS (EAST) LIMITED

CIN : L15122WB2007PLC162762

Regd. Off.: Hyatt Regency Kolkata Hotel, JA-1, Sector - III, Salt Lake City, Kolkata - 700 106, W.B., India
Tel: 033 6820 1344 / 1346, Fax : 033 2335 8246, E-mail : clocs@ahleast.com, Website : www.ahleast.com

4th August, 2026

The Manager Listing Department BSE Limited Phiroze Jeejeebhoy Towers Dalal Street <u>Mumbai – 400 001</u>	The Manager Listing Department National Stock Exchange of India Ltd Exchange Plaza, C/1, Block G Bandra Kurla Complex, Bandra (E) <u>Mumbai – 400 051</u>
Type of Security: Equity shares Script Code : 533227	Type of Security: Equity shares NSE Symbol : AHLEAST

Madam/ Sir,

Sub: Submission of the copies of newspaper advertisement for 19th Annual General Meeting of the Company.

Pursuant to Regulations 30 and 47(1) of the Listing Regulations, 2015, please find enclosed the copies of the advertisement published on even date in the newspapers viz, “Business Standard” (English) and “Ekdin” (Bengali) in respect of the Notice of AGM, e-voting information and book closure.

The same is also available on the website of the Company at www.ahleast.com.

This is for your information and dissemination.

Thanking you.

Yours truly,

For Asian Hotels (East) Limited

Saumen Chatterjee
Chief Legal Officer &
Company Secretary



Encl: as above

OWNER OF



HYATT
REGENCY™
KOLKATA HOTEL

Valuation may blunt Divi's next dose of gains

Strong Q1 numbers, GLP-1 tailwinds, earnings upgrades brighten outlook

RAM PRASAD SAHU
Mumbai, 3 August

The country's largest listed contract development and manufacturing organisation (CDMO), Divi's Laboratories, started 2026-27 (FY27) on a strong note, with its first-quarter (April-June/Q1) results coming in considerably ahead of estimates. While revenue growth was led by the custom synthesis segment, operating profits were lifted by inventory gains.

Brokers expect revenue and margins to post robust growth over the next couple of years, driven by opportunities in glucagon-like peptide (GLP-1) drugs for diabetes and weight loss. Brokerages remain positive on the CDMO major's outlook and have also raised their FY27 and 2027-28 (FY28) earnings estimates. Given the Q1 performance and outlook, the stock was among the top gainers in the BSE 100 index, rising about 3.3 per cent and adding to its 26 per cent gains over the past month.


Aided by the custom synthesis segment, which accounted for 60 per cent of revenue, and currency tailwinds, the company's revenue grew 27.8 per cent year-on-year (Y-o-Y) and 8.8 per cent sequentially. The company said revenue growth in the custom synthesis segment was driven by the commencement of three capital expenditure projects entering the validation stage. While the custom synthesis segment reported 45 per cent Y-o-Y growth, generic active pharmaceutical ingredients grew 6 per cent and nutraceuticals rose 19 per cent.

The revenue beat, according to Systematix Research, was aided by robust execution across commercial molecules, a higher contribution from commercial manufacturing

Healthy signs

— Divi's Laboratories — BSE 100

Base: 100



Sources: Bloomberg, BSE

programmes, and a favourable product mix. The generics business marginally underperformed due to continued pricing pressure, while nutraceuticals delivered a stronger-than-expected performance, supported by healthy global demand and continued portfolio expansion, it added. While the brokerage has marginally revised its estimates following a strong Q1, it has maintained a "hold" rating with a target price of ₹7,959, as the sharp run-up in the stock largely reflects the improving business outlook, limiting meaningful upside from current levels.

ICICI Securities is also positive about the opportunity in custom synthesis projects, though it believes the current valuation adequately factors in the medium-term opportunity. While the brokerage has raised its FY27/FY28 earnings per share estimates by 6-9 per cent to reflect better margins, it has downgraded the stock to a "sell" rating with a target price of ₹6,500.

The operational performance also exceeded expectations, with gross profit rising 44 per cent, about twice what the Street had estimated. Gross margins expanded by 766 basis points (bps) Y-o-Y to 68 per cent, driven by a richer custom synthesis mix and favourable inventory movements. Operating profit grew 72 per cent Y-o-Y, while operating

margins expanded by 1,050 bps Y-o-Y to 41 per cent on the back of operating leverage and manufacturing efficiencies. These gains came despite employee expenses rising 20 per cent Y-o-Y and other expenses increasing 12 per cent.

The firm reiterated its confidence in sustaining double-digit revenue growth over the medium term, supported by the commercialisation of validation projects, peptide opportunities, ongoing capacity additions, and continued momentum in the custom synthesis business.

Analysts Maitri Sheth and Stuti Bagadia of Choice Institutional Equities said the peptide opportunity remains the most significant long-term growth driver, with the management continuing to add capacity in response to strong customer demand. In addition, 18-20 projects are already under commercialisation, highlighting a broad and healthy pipeline that should support sustained growth over the medium term, they said.

Supported by improving backward integration benefits and operating leverage, the brokerage has revised its FY27/FY28 earnings estimates upwards by 4.6 per cent and 2.9 per cent, respectively. It, however, maintains a "reduce" rating with a revised target price of ₹8,355.



YOUR MONEY

PROTECTION AGAINST DREADED DISEASES

Buy a mix of indemnity and benefit plans

KARTHIK JEROME

AstraZeneca Pharma India recently purchased a group cancer care policy over and above its existing group health insurance policy for employees, according to a media report. Some companies also offer group critical illness plans. Most companies in India, however, only provide group medical insurance of around ₹3 lakh to ₹5 lakh, while treating a dreaded disease such as cancer can cost several times more.

The majority of employees do not offer a topup cover or a critical illness cover. "An employer cover may be inadequate. It also ends when the employee changes jobs or retires," says Arun Ramamurthy, cofounder, Staywell Health. Employees must, therefore, build their own insurance portfolios.

Exorbitant costs

Cancer, heart ailments and organ transplants can devastate household finances. "Several cancer claims we witnessed in recent times ranged from ₹50 lakh to ₹75 lakh in a year. The cost of treating cancer is rising, partly because more sophisticated drugs and treatments are

being deployed," says Kapil Mehta, cofounder, SecureNow Insurance Broker. Liver and lung transplants can cost ₹30 lakh to ₹50 lakh.

Buy adequate base plan

Buy a base health cover that is adequate for the next five years. Purchase a high sum insured early, since increasing it may become difficult if one develops an ailment. "The cover should factor in medical inflation of 14-16 per cent," says Mehta. He suggests starting with at least ₹50 lakh.

Add a super topup

Experts suggest combining an adequate base cover with a super topup, which also covers hospitalisation expenses. "This structure can provide a high sum insured without requiring a large outlay," says Mehta. A super topup pays after the

policyholder meets the deductible, typically through the base policy. An individual could combine a ₹20 lakh base cover with a ₹30 lakh or ₹80 lakh super topup. "For a healthy 45-year-old with ₹20 lakh of base cover, an ₹80 lakh super topup would cost roughly ₹8,000-₹15,000 a year," says Ramamurthy. Buy before health issues develop. "Ensure that the deductible matches the base policy. Check the waiting periods, exclusions and the insurer's claim-settlement record," says Ramamurthy.

Buy critical illness cover next

Buy a critical illness plan only after purchasing sufficient base health insurance and a super topup. The first two are indemnity covers, while a critical illness policy pays a lumpsum upon diagnosis of a covered illness.

"Critical illness cover should supplement comprehensive health insurance rather than replace it," says Siddharth Singhal, head of health insurance, Policybazaar.

A dreaded disease can affect household income for 12-18 months. Another earning member may have to reduce their work hours to provide care. "The lumpsum payout can reduce the financial burden created by a lower household income," says Milind Tayde, head - employee benefits, Anand Rathi Insurance Brokers. Policyholders can use the payout without restric-

tions. "It can be used for outpatient care, diagnostics, chemotherapy, heightened nutritional needs and physiotherapy," says Tayde.

The minimum sum insured should be ₹10 lakh, though customers may choose ₹50 lakh or more. "The cover should meet monthly recurring expenses for two to three years. It should also account for outstanding loans and cost components that health insurance claims do not pay," says Tayde.

Check the lumpsum amount payable. "Prefer a policy with a longer list of covered critical illnesses," says Singhal. Also understand the definitions and claim triggers. "Some policies cover more than 40 illnesses but impose severity conditions that make claim payment almost impossible," says Tayde.

Also check the survival period - the minimum time the policyholder must survive after diagnosis for the claim to become payable. "A typical survival period is 15 days. Some policies offer seven days. A shorter survival period is preferable but may cost more," says Singhal.

Build a medical corpus

A health corpus can meet expenses excluded because of pre-existing disease waiting periods. "It can also meet costs arising from sub-limits, consumables and recurring post-treatment care," says Abhishek Kumar, Sebi-registered investment advisor and founder, SahajMoney.com.

He suggests a healthcare corpus of around ₹5 lakh to ₹10 lakh, depending on medical history and insurance limits. The money should be kept in liquid, low-risk instruments for easy access during planned procedures or sudden medical emergencies.

Cost of critical illness covers

Insurer	Plan name	Sum insured (₹ lakh)	Annual premium (₹)	No. of illnesses covered
Niva Bupa	Criticare Cover	15	5,011	20
Aditya Birla	Critical Illness	15	6,161	64
Tata AIA	Sampoorna Care	20	16,912	Only cancer

Premiums are for a 45-year-old male living in Delhi; this is not an exhaustive list
Source: Policybazaar

August financial deadlines: Key tax, banking and market changes to track

August brings several financial deadlines and rule changes that taxpayers, borrowers, investors, and bank customers should note.

The most important deadline is August 31, when self-employed professionals, freelancers and small business owners filing ITR-3 or ITR-4 (not subject to tax audit) must submit their income tax

returns. Missing the deadline may attract a late fee of up to ₹5,000, besides interest on unpaid tax, where applicable. Reserve Bank of India's (RBI's) Monetary Policy Committee (MPC) will announce its policy decision on August 5.

Any change in RBI's stance could influence home loan equated-monthly instalments,

lending rates and fixed deposit returns in the coming months.

Investors should also note that the Securities and Exchange Board of India's (Sebi's) revised trading framework has come into effect. It introduced a closing auction session for futures and options (F&O)-eligible stocks and extended derivatives trading hours.

What you should do:

- File ITR-3 or ITR-4 before August 31, if applicable
- Track the RBI policy announcement for possible impact on loans and fixed deposits
- Check whether your bank has revised service charges from August
- Familiarise yourself with Sebi's revised trading timings.

COMPILED BY AMIT KUMAR

KESORAM INDUSTRIES LIMITED
Regd. Office: 9/1 R. N. Mukherjee Road, Kolkata -700 001
CIN: L17119WB1919PLC003429
Phone: 033-2243 5453, 2242 9454, 2213 5121
Website: www.kesocorp.com; E-mail: corporate@kesoram.com
**CORRIGENDUM TO THE ANNUAL REPORT
FOR THE FINANCIAL YEAR ENDED 31 MARCH 2026**
It has come to the notice of the Company that, due to an inadvertent oversight, the following information appearing in the Annual Report requires correction:

Reference	Existing Text	To be read as
Page -48 point 2(ii) (Forms part of Corporate Governance Report)	Satish Narain Jajoo Directorship in other listed entity – NIL Category: N.A.	Satish Narain Jajoo Directorship in other listed entity -1 Category: Non Executive Independent Director
Page -139 point 36(A)(V)(A) Page -215 point 44(A)(IV)(9) (Forms part of Notes to accounts)	Entity controlled or jointly controlled by the Key Managerial Personnel	Entity controlled or jointly controlled by Promoter or Promoter Group

All other contents of the Annual Report shall remain unchanged.
This Corrigendum forms an integral part of the Annual Report for the Financial Year ended 31 March 2026 and should be read in conjunction with the Annual Report.

For Kesoram Industries Limited

Snehaa Shaw
Company Secretary & Compliance Officer
Membership No.: A29991

Place: Kolkata

Date: 3rd August 2026

SMALL INDUSTRIES DEVELOPMENT BANK OF INDIA
GeM BID NOTICE
SIDBI invites eligible bidders to submit bids in GeM Portal for following:

Bid Description	GeM Bid Reference No.
Request for proposal for Network Transformation through Implementation of SDN-Based Spine-Leaf Architecture at Bank's Data Center and Disaster Recovery Site.	GEM/2026/B/7766640
Request for proposal for Renewal of Subscription to Zscaler Platform.	GEM/2026/B/7739835

For detailed bid documents, please visit **GeM Portal (gem.gov.in)** or our website at **www.sidbi.in**. Addendum/Corrigendum, if any, will be published on the above-mentioned websites only.

PUBLIC NOTICE

NOTICE IS HEREBY GIVEN to the public at large that **Axis Securities Limited ("ASL")**, is a registered under the Companies Act, 2013 with its principal place of business located at **Unit 002(A), Amiti Building, Piramal Corporate Park, Kamani Junction, LBS Marg, Kurla (West), Mumbai – 400070**. One **Ms. Rekha Aggarwal**, aged 40 years, resident of House No. 2034 A, First Floor, H.I.G, Sector -3, VTC: Ballabgarh, P O: Ballabgarh, District Faridabad, Haryana, Pincode: 121004 **an Business Associate of Axis Securities Limited (Company) had been terminated from business.**

Please note Mrs Rekha Aggarwal is no longer associated with the Company as Business Associate/Authorized person or in any manner w.e.f. 18-06-2026.

Please note that she is not authorized to represent the Company in any matter whatsoever. Any person or entity dealing with her shall do so at his own risk and responsibility. The public at large is advised not to deal with any individuals, entity, firm etc. who are impersonating in the name of the Company by using various means such as WhatsApp group, fake links, fake website, fake investment profiles etc. The Company shall not be responsible for any losses incurred by the public as a result of such impersonation being carried in its name.

For and on behalf of

Axis Securities Limited

Official Website: <https://simplehai.axisdirect.in/>



Asian Hotels (East) Limited
CIN No.: L15122WB2007PLC162762
Regd. Office: Hyatt Regency, Kolkata,
JA-1, Sector-III, Salt Lake City, Kolkata 700 106, W.B, India
Phone: 033 6820 1344/1346, Fax: 033 2335 8246
Email ID: investorrelations@ahleast.com Website: www.ahleast.com
**Information regarding 19th Annual General Meeting
to be held through video conferencing**
Shareholders may note that the 19th Annual General Meeting (AGM) of the Company will be held on Thursday, 27th August, 2026 at 11:00 a.m. through video conferencing (VC) in compliance with the applicable provisions of the Companies Act, 2013 and the rules made thereunder and the SEBI (LODR) Regulations, 2015 along with applicable circulars issued in this regard by the MCA and SEBI to transact the businesses that will be set forth in the Notice of the AGM.
In compliance with the above circulars, electronic copies of the Notice of the 19th AGM and Annual Report for the financial year ended 2025-26 will be sent to all the shareholders whose email addresses are registered with the Company/ Registrar and Share Transfer Agent/ Depository Participant(s). As per Regulation 36(1)(b) of the SEBI (LODR) Regulations, 2015, a letter providing the web-link, including the exact path, where complete details of the Annual Report will be available, will be dispatched to those shareholder(s) who have not registered their email addresses with the Company/ any depository. Notice of the 19th AGM and Annual Report for the financial year ended 2025-26 will also be made available on the respective websites: www.ahleast.com, <https://www.bseindia.com/> and <https://www.nseindia.com/>. The physical copies of the Notice along with the Annual Report for the financial year ended 2025-26 shall be sent to those shareholders who will request for the same.
Manner of casting votes through e-voting
Detailed instructions for e-voting including remote e-voting and e-voting during AGM will be provided in the Notice of the AGM to the shareholders of the Company.
Book Closure
Pursuant to Section 91 of the Companies Act, 2013 and Regulation 42 of the SEBI (LODR) Regulations, 2015, the Register of Members and the Share Transfer Books of the Company will remain closed from Saturday, 22nd August, 2026 to Thursday, 27th August, 2026 (both days inclusive).

For Asian Hotels (East) Limited

Sd/-
Saumen Chatterjee
Chief Legal Officer & Company Secretary

Place: Kolkata

Date : 3rd August, 2026

— TENDER CARE —

— Advertorial

SHRI PARESH RANPARA TAKES OVER AS DIRECTOR (PERSONNEL), NHPC LIMITED

Shri Paresh Ranpara has assumed charge as Director (Personnel) of NHPC Limited, a premier Navratna Public Sector Enterprise under the Ministry of Power, Government of India, on 30 July 2026. Prior to his appointment as Director (Personnel), NHPC, Shri Ranpara was serving as Director (Human Resources) at Grid-India, where he was responsible for providing strategic leadership in the areas of human resource management, talent development, organizational capability building and workforce planning.



Shri Ranpara is a Human Resource professional with over 31 years of rich experience in the power sector, spanning both public and private organizations. He holds a Master of Social Work (MSW) from The Maharaja Sayajirao University of Baroda and a Bachelor of Business Administration (BBA) from Sardar Patel University. He is also a Certified Assessor from XLRI, Jamshedpur.

REC AND PFC SIGN ₹26,850 CRORE COMMON LOAN AGREEMENT WITH MUNPL FOR 2,400 MW MEJA THERMAL POWER PROJECT STAGE-II

REC Limited and PFC Limited, Maharatna CPSEs under the Ministry of Power and leading Infrastructure Financing NBFCs, have signed Common Loan Agreement with Meja Urja Nigam Private Limited (MUNPL), a 50:50 Joint Venture between NTPC Limited & Uttar Pradesh Rajya Vidyut Utpadan Nigam Limited (UPRVUNL) for total loan amount of Rs. 26,850 Crore for the establishment of 2400 MW Meja TPP Stage-II Ultra-Super Critical units of 800 MW under Stage-II (3x800 MW) with Air Cooled Condenser (ACC) system at Meja Tehsil, Prayagraj District, Uttar Pradesh with an estimated project completion cost of Rs. 38,357.81 crore. REC is the lead financier of the project and the loan has been funded in 50:50 by REC and PFC. The Loan Documents were signed at Prayagraj, Uttar Pradesh by Mr. Srinivasa Rao Gaddamanugu, Chief Executive Officer, MUNPL, Mr. Shambhu Shankar Gupta, Chief General Manager, REC Regional Office Lucknow and Ms Shelly Gupta, GM, PFC, in the presence of Mr Angshu Barua, Chief Financial Officer, MUNPL; Mr. H. K. Das, Executive Director, PFC and Mr. D. B. Londhe, Executive Director, REC.

BALMER LAWRIE ANNOUNCES FIRST QUARTER RESULTS

Balmer Lawrie & Co. Ltd., a Mini Ratna Category – I PSE with diversified business portfolios, announced the first quarter results as per the accounts adopted for the quarter ending 30 June 2026. The results were approved by the Board in its Meeting held on 01 August 2026. The net total income for the first quarter increased by 9.82% and stood at Rs. 752.54 crores compared to Rs. 685.28 crores for the same period last year. The Profit Before Tax (PBT) saw a jump of 4.98% and rose to Rs. 79.12 crores for the quarter ended 30 June 2026 as compared to Rs. 75.37 crores for the same quarter last year. Correspondingly, the net profit (PAT) during the quarter rose by 3.09% to Rs.57.66 crores compared to Rs. 55.93 crores for the corresponding period last year.

NBCC SIGNS LANDMARK AGREEMENT WITH GOVERNMENT OF THE REPUBLIC OF SEYCHELLES FOR CONSTRUCTION OF 1008 HOUSING UNITS

NBCC (India) Limited, a Navratna CPSE under the Ministry of Housing and Urban Affairs, Government of India, has signed a landmark agreement with the Government of the Republic of Seychelles for the construction of the Île Aurore Housing Project, comprising 1008 affordable housing units along



with associated infrastructure in Seychelles. The agreement was signed on July 29 in the august presence of H.E. Sebastian Pillay, Vice President of the Republic of Seychelles, and Dr. K. P. Mahadevaswamy, Chairman & Managing Director, NBCC (India) Limited.

The agreement was formally signed by Mr. Joseph Francois, Secretary of State, Lands, Housing and Infrastructure, Government of the Republic of Seychelles, and Mr. Pradeep Sharma, Executive Director (Engineering), NBCC (India) Limited.

BANK OF MAHARASHTRA SLASHES ITS HOME LOAN RATES TO 7% WITH ZERO PROCESSING FEES AND DOCUMENTATION CHARGES

Bank of Maharashtra (BoM) announced the launch of a special limited period - Monsoon Dhamaka offer with reduction in its home loan rates starting from 7% p.a. along with complete waiver of processing fees and documentation charges. This triple benefit of reduced interest rates with zero processing fees and documentation charges reflects bank's commitment to offer best financing solutions to all its customers and help them fulfil their dreams.

The 7% p.a. interest rate on Home Loans & 7.45% p.a. interest rate on car loan are priced among the lowest in the industry which along with zero processing fees and documentation charges significantly reduce the EMI burden on the customers. All the customers can apply directly through <https://digileads.bankofmaharashtra.bank.in/retail-loan/>, the Bank's dedicated application link for retail loans for quick processing of its loan applications.

RECPDCL HANDS OVER RYAPTE POWER TRANSMISSION LIMITED, A SPV OF INTER STATE TRANSMISSION PROJECT, TO M/S THE TATA POWER COMPANY LIMITED

REC Power Development and Consultancy Limited (RECPDCL), a wholly owned subsidiary of REC Limited, a Maharatna CPSE under the Ministry of Power, handed over Ryapte Power Transmission Limited, the project-specific Special Purpose Vehicle (SPV), to the successful bidder, M/s The Tata Power Company Limited, on 30 July 2026. M/s The Tata Power Company Limited emerged as the successful bidder through the Tariff-Based Competitive Bidding (TBCB) process conducted by RECPDCL, the Bid Process Coordinator, for development of intra-state transmission project of Karnataka viz. "Evacuation Scheme for 2000MW solar park at Ryapte Village, Tumkur District" on a Build, Own, Operate and Transfer (BOOT) basis. The SPV was handed over by Smt. Monisha Barua, GM & HoD, RECPDCL to Mr. Tarun Katiyar, CEO & MD, TPTCL, in the presence of Managing Director, KPTCL and other senior officials from KPTCL, The Tata Power Company Limited and RECPDCL.



